Physician profile
Kayvan Haddadan
NPI 1538127832
$15,358.58
in general payments reported to CMS, 2019-2025
66 companies · $3,701 in 2025
The $3,701 reported for 2025 was more than what 88% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,345 · 2020: $864 · 2021: $1,356 · 2022: $2,267 · 2023: $3,183 · 2024: $1,643 · 2025: $3,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,858 · Travel and Lodging: $1,457 · Long Term Medical Supply Or Device Loan: $159 · Education: $52.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,858.42 |
| Travel and Lodging | $1,456.58 |
| Long Term Medical Supply Or Device Loan | $159.18 |
| Education | $52.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,393.82 | 2021-2024 | Synchromedii, Intellis Adaptivestim, V-Loc 180 |
| Abbvie INC. | $1,053.94 | 2019-2025 | |
| Boston Scientific Corporation | $961.40 | 2019-2025 | Infinion 16, General - Therapies, Click |
| Electronic Waveform Lab, INC. | $946.03 | 2021-2025 | |
| Abbott Laboratories | $827.32 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $555.99 | 2019-2024 | Senza |
| Forte Bio-Pharma LLC | $533.35 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $525.96 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $491.97 | 2019-2025 | Belbuca, Xtampza |
| Neuronetics, INC. | $460.69 | 2021-2022 | |
| Curonix LLC | $458.38 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $417.53 | 2019-2025 | Sprint Pns System |
| Globus Medical, INC. | $355.19 | 2025 | Vyrsa V1, Senza, Omnia |
| Pfizer INC. | $348.71 | 2019-2024 | |
| Wenzel Spine, INC. | $273.89 | 2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayvan Haddadan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.